Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rocio Violeta Gamboa-Cardenas"'
Autor:
Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Risto Alfredo Perich-Campos, Claudia Elera-Fitzcarrald, Cristina Reátegui-Sokolova, Rocio Violeta Gamboa-Cardenas, Mariela Medina, Victor Román Pimentel-Quiroz, Zoila Rodriguez-Bellido, Cesar Augusto Pastor-Asurza
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss 1 (2023)
Objective To determine the possible predictive value of self-efficacy on health-related quality of life (HRQoL) in patients with SLE.Methods Patients with SLE from the Almenara Lupus Cohort were included. Self-efficacy was ascertained with the six do
Externí odkaz:
https://doaj.org/article/f5084bb333f4458299fb8e0cce9165c2
Autor:
Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Risto Alfredo Perich-Campos, Claudia Elera-Fitzcarrald, Cristina Reátegui-Sokolova, Rocio Violeta Gamboa-Cardenas, Mariela Medina, Victor Román Pimentel-Quiroz, Cesar Augusto Pastor-Asurza
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss 1 (2022)
Background Flares in patients with SLE, regardless of their severity, have been associated with damage accrual. However, their impact on health-related quality of life (HRQoL) has not been fully evaluated. In fact, disease activity is only minimally
Externí odkaz:
https://doaj.org/article/2606d90e58154cd8ae4835246fd5aec8
Autor:
Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Risto Alfredo Perich-Campos, Claudia Elera-Fitzcarrald, Cristina Reátegui-Sokolova, Rocio Violeta Gamboa-Cardenas, Mariela Medina, Francisco Zevallos, Victor Román Pimentel-Quiroz, Jorge Mariano Cucho-Venegas, José Alfaro-Lozano, Zoila Rodriguez-Bellido, Cesar Augusto Pastor-Asurza
Publikováno v:
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Introduction Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined.Ob
Externí odkaz:
https://doaj.org/article/62bb2558f7c34188929fd16f5cca2257
Autor:
Manuel Francisco Ugarte-Gil, Graciela Alarcon, Risto Alfredo Perich-Campos, Claudia Elera-Fitzcarrald, Cristina Reátegui-Sokolova, Rocio Violeta Gamboa-Cardenas, Victor Román Pimentel-Quiroz, Zoila Rodriguez-Bellido, Cesar Augusto Pastor-Asurza, Anca D Askanase, Paola Zeña-Huancas, Samira Garcia-Hirsh, Luciana Gil, Joan Merrill
Publikováno v:
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Objective The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinician-reported outcome (ClinRO) and the LFA-REAL patient-reported outcome (PRO) were developed in order to capture manifestations of SLE from the perspecti
Externí odkaz:
https://doaj.org/article/bcec9c2fff9a4e8e88ac724e40911ff4
Autor:
Edward Mezones-Holguin, Rocio Violeta Gamboa-Cardenas, Gadwyn Sanchez-Felix, José Chávez-Corrales, Luis Miguel Helguero-Santin, Luis Max Laban Seminario, Paula Alejandra Burela-Prado, Maribel Marilu Castro-Reyes, Fabian Fiestas
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic
Externí odkaz:
https://doaj.org/article/a413291d6b2c40b38e015aa88857a8c3
Autor:
Manuel Francisco Ugarte-Gil, Rocio Violeta Gamboa-Cardenas, Cristina Reátegui-Sokolova, Victor Román Pimentel-Quiroz, Mariela Medina, Claudia Elera-Fitzcarrald, Francisco Zevallos, Cesar Augusto Pastor-Asurza, Jeniffer Lofland, Federico Zazzetti, Chetan S Karyekar, Graciela S Alarcón, Risto Alfredo Perich-Campos
Publikováno v:
Lupus sciencemedicine. 9(1)
ObjectiveTo determine if achieving lupus low disease activity state (LLDAS) or remission prevents damage accrual in a primarily Mestizo population.MethodsPatients with SLE from a single-centre cohort with at least two visits occurring every 6 months
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ff33f10a29830b94759365080b9174c
https://pubmed.ncbi.nlm.nih.gov/35193948
https://pubmed.ncbi.nlm.nih.gov/35193948
Autor:
Maribel Marilu Castro-Reyes, Paula Alejandra Burela-Prado, Gadwyn Sanchez-Felix, José Chávez-Corrales, L.M. Helguero-Santin, Rocio Violeta Gamboa-Cardenas, Edward Mezones-Holguín, Luis Max Laban Seminario, Fabián Fiestas
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology
Frontiers in Pharmacology
Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea695a56e896bc59707774407444716
https://www.frontiersin.org/article/10.3389/fphar.2019.01010/full
https://www.frontiersin.org/article/10.3389/fphar.2019.01010/full